Technology

Bicycle Therapeutics

$29.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.70 (+9.99%) As of 8:50 PM UTC today

Why Robinhood?

You can buy or sell BCYC and other stocks, options, and ETFs commission-free!

About BCYC

Bicycle Therapeutics plc American Depositary Shares, also called Bicycle Therapeutics, is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom. The listed name for BCYC is Bicycle Therapeutics plc American Depositary Shares.

CEO
Kevin Lee
Employees
72
Headquarters
Cambridge, Cambridgeshire
Founded
2009
Market Cap
461.24M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
238.13K
High Today
$31.02
Low Today
$26.97
Open Price
$28.05
Volume
624.10K
52 Week High
$31.02
52 Week Low
$10.26

Collections

BCYC Earnings

-$1.40
-$0.93
-$0.47
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

KSU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure